Viatris Inc. - Common Stock (NQ:VTRS)

The market is a weighing machine in the long run, meaning these bargain stocks will deliver impressive forward returns.

3 Bargain Stocks to Snatch Up Before They Bounce Back ↗

February 26, 2024

Most of the aforementioned group of quotable experts expect some mean reversion for the top stocks in the S&P 500 and counsel avoiding market cap weighting in favor of equal weighting.

5 Value Stocks In The Healthcare Sector ↗

February 26, 2024

Via Benzinga

The Terrible Ten ↗

February 23, 2024

Many strategists recommend equal weighting over cap-weighting, claiming that over time, equal weighting always outperforms.

Topics Stocks

The Terrible Ten ↗

February 12, 2024

These two blue chip stocks offer top-notch yields, attractive valuations, and solid long-term prospects.

(VTRS) - Analyzing Viatris's Short Interest ↗

January 23, 2024

Via Benzinga

Recap: Viatris Q3 Earnings ↗

November 07, 2023

Via Benzinga

2 Top Value Stocks to Buy in October ↗

October 08, 2023

The S&P 500 is up just 0.2% in 2024. These stocks are off to a strong start.

These 9 Stocks Are Running To Start 2024 ↗

January 14, 2024

Via Investor's Business Daily

Topics Stocks

Regeneron Pharma's Pipeline Makes This Analyst Turn Bullish ↗

January 12, 2024

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) won a lawsuit last month against Viatris Inc (NASDAQ: VTRS)

Via Benzinga

Topics Lawsuit

Beat Inflation With These 3 High-Yielding Dividend Stocks In Health Care Sector From Wall Street's Most Accurate Analysts ↗

January 12, 2024

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...

Via Benzinga

Topics Economy

Are defensive sectors ready to outshine growth in 2024?

January 06, 2024

Is 2024 the year defensive stocks rotate into leadership? As the year gets underway, defensives such as healthcare, energy, utilities and consumer staples lead.

Via MarketBeat

Why Is Lung Disease Focused Theravance Biopharma Stock Trading Lower Today? ↗

January 05, 2024

Theravance Biopharma Inc (NASDAQ: TBPH) announced results from the Phase 4 PIFR-2 study of Yupelri (revefenacin) inhalation solution, the only once-daily, nebulized long-acting muscarinic antagonist...

Via Benzinga

Tech Sell-Off Triggers Market Reset: Value Stocks Reach 7-Month High Versus Growth ↗

January 03, 2024

U.S. stock market suffered worst start in two decades, tech sell-off led to cautious investor shift to value stocks, notably IUSV & IUSG ETFs + top gainers MRNA, VTRS, TNL, LVS & VAC.

Via Benzinga

Topics ETFs

VIATRIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Viatris Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

January 01, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

Regeneron Celebrates Legal Win: Court Upholds Eylea Medication Patent ↗

December 28, 2023

Wednesday, a court ruling that found Viatris Inc's (NASDAQ:

Via Benzinga

3 Minutes To Boost Your Earnings: 3 Stocks With Over 3% Dividend Yields In Health Care Sector From Wall Street's Most Accurate Analysts ↗

December 27, 2023

Via Benzinga

A Look Into Healthcare Sector Value Stocks ↗

December 25, 2023

Via Benzinga

These 3 Dividend Stocks Are Undervalued Using This Key Valuation Metric ↗

November 30, 2023

Book value is a valuable metric for discovering undervalued stocks. These 3 dividend payers are trading below book value.

Often the best investments are out-of-favor and trade at silly cheap valuations. Check out three such growth stocks with huge upside.

Buy Alert: Analysts Say These 3 Growth Stocks Could Double in 2024 ↗

November 30, 2023

Each of these seven low P/E value stocks trades for under 10 times earnings, but could rise to a much higher valuation as sentiment improves.

7 Low P/E Stocks Poised to Rebound ↗

November 20, 2023

Week In Review: Legend Partners DLL3 CAR-T Candidate With Novartis In $1.2 Billion Deal ↗

November 18, 2023

Legend Biotech partnered its DLL3 CAR-T candidates to Novartis in a $1.2 billion agreement, with $100 million offered upfront. Novartis will own worldwide rights to develop, manufacture, and...

There aren’t too many large-cap stocks in the S&P 500 trading below book value. But here are three possibilities.

5 Value Stocks To Watch In The Healthcare Sector ↗

November 13, 2023

Via Benzinga

3 Large-Cap Stocks to Buy Trading Below Book Value ↗

November 07, 2023

Ozempic Just Shrugged Off a Challenge From Viatris. What Does This Mean for Investors? ↗

Topics Stocks

October 31, 2023

Viatris now faces a narrower path to commercializing a generic copy of Ozempic.

Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter.

Earnings Scheduled For November 7, 2023 ↗

November 07, 2023

Via Benzinga

Viatris Just Sold Off 3 Key Segments. Is It Still a Buy? ↗

October 13, 2023

There's a chance shareholders won't notice any difference.

These stocks may not be for everyone, but income-seekers might find what they're looking for in them.

2 Healthcare Dividend Stocks You'd Regret Not Buying on the Dip ↗

October 08, 2023